Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Cancer Retrieve available abstracts of 32 articles: HTML format

Single Articles

September 2025
1. YOSHINO Y, Furusawa A, Nara K, Taguchi A, et al
   Optimizing treatment for platinum-resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab.
   Cancer. 2025;131:e70071.
   PubMed     Abstract available
   
   
   May 2025
2. DUSKA LR, Lim J, Calderon Boyle TA, Guinter M, et al
   The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
   Cancer. 2025;131:e35821.
   PubMed     Abstract available
   
   
   
3. SCHNEIDER DT, Witowski A, Abele M, Benesch M, et al
   Testicular and ovarian Juvenile granulosa cell tumors in children and adolescents: Analysis of 113 patients registered to the German Registry for Rare Pediatric Tumors (STEP).
   Cancer. 2025;131:e35861.
   PubMed     Abstract available
   
   
   
4. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
   Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
   Cancer. 2025;131:e35862.
   PubMed     Abstract available
   
   
   April 2025
5. FREY MK, Liu JF
   Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer.
   Cancer. 2025;131:e35800.
   PubMed    
   
   
   March 2025
6. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
   The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
   Cancer. 2025;131:e35804.
   PubMed     Abstract available
   
   
   
7. NIERENGARTEN MB
   More evidence on benefits of HIPEC for recurrent ovarian cancer.
   Cancer. 2025;131:e35754.
   PubMed    
   
   
   February 2025
8. HIPPALGAONKAR N, Huo D, Hoskins KF
   The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome.
   Cancer. 2025;131:e35722.
   PubMed    
   
   
   
9. TEMKIN SM
   Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer.
   Cancer. 2025;131:e35735.
   PubMed    
   
   
   January 2025
10. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    PubMed     Abstract available
    
    
    
11. LIU YL, Mathews CA, Simpkins F, Cadoo KA, et al
    Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
    Cancer. 2025;131:e35707.
    PubMed     Abstract available
    
    
    
12. MAHALINGAM D, Owonikoko TK, Delpassand E, Mulcahy MF, et al
    A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
    Cancer. 2025;131:e35680.
    PubMed     Abstract available
    
    
    
13. RICHARDS AR, Johnson CE, Montalvo NR, Alberg AJ, et al
    Comorbid conditions and survival among Black women with ovarian cancer.
    Cancer. 2025;131:e35694.
    PubMed     Abstract available
    
    
    November 2024
14. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    PubMed    
    
    
    August 2024
15. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    PubMed     Abstract available
    
    
    June 2024
16. 
    Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    PubMed    
    
    
    January 2024
17. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    PubMed     Abstract available
    
    
    
18. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed     Abstract available
    
    
    December 2023
19. RIMEL BJ, Enserro D, Bender DP, Jackson CG, et al
    NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Cancer. 2023 Dec 21. doi: 10.1002/cncr.35151.
    PubMed     Abstract available
    
    
    
20. LUMISH MA, Kohn EC, Tew WP
    Top advances of the year: Ovarian cancer.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35135.
    PubMed     Abstract available
    
    
    November 2023
21. HINCHCLIFF EM, Knisely A, Adjei N, Fellman B, et al
    Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Cancer. 2023 Nov 27. doi: 10.1002/cncr.35126.
    PubMed     Abstract available
    
    
    October 2023
22. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    PubMed     Abstract available
    
    
    September 2023
23. NIERENGARTEN MB
    New standard of care for platinum-resistant ovarian cancer.
    Cancer. 2023;129:2601-2602.
    PubMed    
    
    
    July 2023
24. WHITE VM, Alexiadis M, Eroh KD, Ackermann MK, et al
    How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.
    Cancer. 2023;129:2224-2234.
    PubMed     Abstract available
    
    
    June 2023
25. GRISHAM RN, Manning-Geist BL, Chui MH
    The highs and lows of serous ovarian cancer.
    Cancer. 2023 Jun 27. doi: 10.1002/cncr.34903.
    PubMed     Abstract available
    
    
    
26. MEDINA HN, Penedo FJ, Joachim C, Deloumeaux J, et al
    Endometrial cancer risk and trends among distinct African descent populations.
    Cancer. 2023 Jun 26. doi: 10.1002/cncr.34789.
    PubMed     Abstract available
    
    
    
27. MIRZA MR, Gonzalez-Martin A, Graybill WS, O'Malley DM, et al
    Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Cancer. 2023;129:1846-1855.
    PubMed     Abstract available
    
    
    May 2023
28. KINDLER HL, Yoo HK, Hettle R, Cui KY, et al
    Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Cancer. 2023;129:1411-1418.
    PubMed     Abstract available
    
    
    March 2023
29. MANNING-GEIST BL, Kahn RM, Nemirovsky D, Girshman J, et al
    Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34753.
    PubMed     Abstract available
    
    
    
30. FOSTER KI, Shaw KRM, Jin J, Westin SN, et al
    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Cancer. 2023 Mar 17. doi: 10.1002/cncr.34724.
    PubMed     Abstract available
    
    
    
31. GRISHAM RN, Manning-Geist BL, Chui MH
    Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34658.
    PubMed    
    
    
    
32. HENDRIKSE CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, et al
    Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34661.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.